{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03668145",
      "OrgStudyIdInfo": {
        "OrgStudyId": "KY20172050-1"
      },
      "Organization": {
        "OrgFullName": "Xijing Hospital of Digestive Diseases",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis",
      "OfficialTitle": "Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis, a Randomized Double-blind Placebo Controlled Trial"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2018",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "November 8, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 31, 2019",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 31, 2020",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "September 10, 2018",
      "StudyFirstSubmitQCDate": "September 10, 2018",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 12, 2018",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "September 10, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 12, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Han Ying",
        "ResponsiblePartyInvestigatorTitle": "Prof. Dr.",
        "ResponsiblePartyInvestigatorAffiliation": "Xijing Hospital of Digestive Diseases"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Xijing Hospital of Digestive Diseases",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Ursodeoxycholic acid is the mainstay treatment medicine for primary biliary cholangitis(PBC). About 1/3 of the patients do not respond to UDCA, which is defined as refractory PBC. Mesenchymal stem cells (MSC) has been reported to improve the outcomes of PBC patients. Randomization controlled studies are needed to confirm the long term effect of MSC treatment for refractory PBC. This study aimed to investigate the safety and efficacy of mesenchymal stem cells in PBC patients that do not respond to UDCA treatment. This study is an double-blind multicenter randomized and placebo-controlled study. Patients with with refractory PBC will be randomly assigned to receive MSC treatment plus UDCA or UDCA alone (control). Three times of MSC infusion (0.1-1x10E6 cells/kg body weight) via peripheral vein will be given to the experimental group (once in 4 weeks). The primary outcome is absolute change in alkaline phosphatase. Secondary outcomes are changes of other liver function indices such as ALT TBIL AST GGT, improve of symptoms and liver histology."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Primary Biliary Cirrhosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Primary Biliary Cirrhosis (now termed as primary biliary cholangitis), mesenchymal stem cell,"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Not Applicable"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignMaskingDescription": "Randomization will be blinded to participant, care provider, investigator and outcome assessors.",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "140",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "MSC group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8 plus UDCA.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Procedure: mesenchymal stem cell transplantation or placebo infusion via peripheral vein"
              ]
            }
          },
          {
            "ArmGroupLabel": "control",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 4, 8 plus UDCA.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Procedure: mesenchymal stem cell transplantation or placebo infusion via peripheral vein"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Procedure",
            "InterventionName": "mesenchymal stem cell transplantation or placebo infusion via peripheral vein",
            "InterventionDescription": "0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "MSC group",
                "control"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change of alkaline phosphatase (ALP)",
            "PrimaryOutcomeDescription": "The absolute value change of ALP after 1 year of the initial stem cell treatment",
            "PrimaryOutcomeTimeFrame": "1 year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change of other liver function indices",
            "SecondaryOutcomeDescription": "The absolute value change of total bilirubin, ALT, AST, GGT after initial stem cell treatment",
            "SecondaryOutcomeTimeFrame": "1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Change of liver histology",
            "SecondaryOutcomeDescription": "histological scores assessed by liver biopsy at baseline and after treatment",
            "SecondaryOutcomeTimeFrame": "1 year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\ninformed consent\nAge between 18-70 years old\nBMI between 17-28\nMeeting at least 2 of the 3 criteria: (1) positive for anti-mitochondial antibody (AMA)；(2) Elevated ALP or GGT；(3) PBC diagnosis confirmed by liver biopsy\nSerum ALP >/=1.67 ULN after at leat 6 months treatment with UDCA 1(3-17mg/kg/day) -\n\nExclusion Criteria:\n\nPregnancy, breast-feeding females\nUse of liver-toxic drugs over 2 week within 6 months prior to recruitment；\nrefractory variceal bleeding, uncontrolled hepatoencephalopathy or uncontrolled ascites.\nAcute of chronic kidney failure.\nCommodities with other liver diseases such as viral hepatitis, alcoholic liver disease, auto-immune hepatitis or liver cancer\nSevere cardiovascular disease；\nliver transplantation listed patients；\nALT/AST over 5xULN，or total bilirubin >85umol/l\nanticipated need for liver transplantation within 1 year according to mayo risk score\nOther candidates who are judged to be not applicable to this study by doctors",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Ying Han, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "862984771539",
            "CentralContactEMail": "guochc@fmmu.edu.cn"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Changcun Guo",
            "LocationStatus": "Recruiting",
            "LocationCity": "Xi'an",
            "LocationState": "Shaanxi",
            "LocationZip": "710032",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Changcun Guo",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "13991900180",
                  "LocationContactEMail": "guochc@sina.com"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Yes",
      "IPDSharingInfoTypeList": {
        "IPDSharingInfoType": [
          "Study Protocol"
        ]
      },
      "IPDSharingTimeFrame": "The data will be available after the completion of the study and before publications for 1 year"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000002761",
            "ConditionMeshTerm": "Cholangitis"
          },
          {
            "ConditionMeshId": "D000008105",
            "ConditionMeshTerm": "Liver Cirrhosis, Biliary"
          },
          {
            "ConditionMeshId": "D000005355",
            "ConditionMeshTerm": "Fibrosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000008103",
            "ConditionAncestorTerm": "Liver Cirrhosis"
          },
          {
            "ConditionAncestorId": "D000008107",
            "ConditionAncestorTerm": "Liver Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          },
          {
            "ConditionAncestorId": "D000001649",
            "ConditionAncestorTerm": "Bile Duct Diseases"
          },
          {
            "ConditionAncestorId": "D000001660",
            "ConditionAncestorTerm": "Biliary Tract Diseases"
          },
          {
            "ConditionAncestorId": "D000002780",
            "ConditionAncestorTerm": "Cholestasis, Intrahepatic"
          },
          {
            "ConditionAncestorId": "D000002779",
            "ConditionAncestorTerm": "Cholestasis"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10255",
            "ConditionBrowseLeafName": "Liver Cirrhosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5154",
            "ConditionBrowseLeafName": "Cholangitis",
            "ConditionBrowseLeafAsFound": "Cholangitis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10257",
            "ConditionBrowseLeafName": "Liver Cirrhosis, Biliary",
            "ConditionBrowseLeafAsFound": "Primary Biliary Cholangitis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M7637",
            "ConditionBrowseLeafName": "Fibrosis",
            "ConditionBrowseLeafAsFound": "Cirrhosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10259",
            "ConditionBrowseLeafName": "Liver Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4087",
            "ConditionBrowseLeafName": "Bile Duct Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4098",
            "ConditionBrowseLeafName": "Biliary Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5171",
            "ConditionBrowseLeafName": "Cholestasis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5172",
            "ConditionBrowseLeafName": "Cholestasis, Intrahepatic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4683",
            "ConditionBrowseLeafName": "Primary Biliary Cholangitis",
            "ConditionBrowseLeafAsFound": "Primary Biliary Cholangitis",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}